GlassScriptPhysician profile
Kristine S Warnes
NPI 1871543264
$66,103.48
in general payments reported to CMS, 2019-2025
10 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $860 · 2022: $5,713 · 2023: $7,592 · 2024: $23K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $5,298 · Food and Beverage: $3,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,353.63 |
| Travel and Lodging | $5,298.49 |
| Food and Beverage | $3,878.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $64,638.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $346.69 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Aimmune Therapeutics, INC. | $287.24 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $245.48 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $203.38 | 2021-2024 | Onzetra Xsail, Contrave |
| Abbvie INC. | $150.84 | 2021-2025 | |
| Vivus LLC | $95.21 | 2024-2025 | Qsymia |
| Astrazeneca Pharmaceuticals LP | $80.67 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.61 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.48 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristine Warnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.